**Core Concept**

Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), exerts its effects through the inhibition of cyclooxygenase (COX) enzymes, which are crucial for the production of prostaglandins and thromboxanes. This mechanism is key to understanding aspirin's analgesic, anti-inflammatory, and antiplatelet properties.

**Why the Correct Answer is Right**

Aspirin selectively inhibits COX-1, an enzyme responsible for the production of thromboxane A2, a potent vasoconstrictor and platelet aggregator. This inhibition leads to a decrease in platelet aggregation, making aspirin an effective antiplatelet agent and an important component in the prevention of cardiovascular events, such as myocardial infarction and stroke. Additionally, aspirin's inhibition of COX-1 and COX-2 (with lower selectivity) reduces prostaglandin synthesis, contributing to its analgesic and anti-inflammatory effects.

**Why Each Wrong Option is Incorrect**

**Option A:** Aspirin is not primarily associated with the inhibition of histone deacetylases (HDACs), which are involved in gene regulation and cell differentiation.

**Option B:** While aspirin does have some effects on the renin-angiotensin-aldosterone system (RAAS), this is not its primary association.

**Option C:** Aspirin is not primarily associated with the inhibition of angiotensin-converting enzyme (ACE), which is a key component of the RAAS.

**Clinical Pearl / High-Yield Fact**

Aspirin's antiplatelet effects are dose-dependent, with lower doses (75-100 mg) providing adequate antiplatelet protection for cardiovascular prevention, while higher doses (300-500 mg) are typically used for acute myocardial infarction and stroke.

**Correct Answer: D. Inhibition of COX-1.**